Nafarelin

Therapeutic

For treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.

Structural features

SMILES

CC(C)C[C@H](NC(=O)[C@@H](CC1=CC2=C(C=CC=C2)C=C1)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O

Sequence

XHWSYXLRPG-NH2

Molar mass

1322.496 g/mol

Constitutional members:

10

Natural amino acids

8

D-Amino acids

1

N-terminus

pyroglutamyl

C-terminus

NH2

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

no

Route of administration

NASAL

Terminal half-life

3 hours

Protein binding

0.8

Absorption and Bioavailability

0.028

References